Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
Andrew Larry Frelinger III, Director Emeritus, Center for Platelet Research Studies Corresponding Faculty, Dept. of Pediatrics at Harvard Medical School, shared on LinkedIn:
”I am very pleased to share this publication which came about through a great collaboration with the Steve Watson lab.
The paper explores activation of GPVI, CLEC-2 and PEAR1 using multivalent nanobodies.
Special thanks to Rachel Lamerton for spearheading the work, Elenya Martin for preparing the nanobodies, and Jax Perry for the performing and analyzing the spectral cytometry assays.
These fantastic tools may aid in the development of assays to assess platelet function disorders.
Enjoy!”
Read the full article in RPTH.
Article: A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Authors: Rachel E. Lamerton, Eleyna M. Martin, Jacqueline Perry, Adam F. Cunningham, Steve P. Watson, Andrew Larry Frelinger III
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?